DFTX Definium Therapeutics, Inc.
Company Analysis
Latest News
🟢 Definium Therapeutics is trading 4.2% up today amid 2.09% biotech sector gains
Definium Therapeutics is trading at $34.36, up +4.22%, with the move appearing consistent with the biotech sector’s reported 2.09% rise. - No clear new...
🔴 Definium Therapeutics falls 4.8% — Biotech Sector Declines Amid Broad Market Rotation
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as represented by the XBI...
🔴 Definium Therapeutics is trading 4.04% down; catalyst remains unclear
Definium Therapeutics is trading 4.04% down at $35.41, with no confirmed company-specific catalyst identified. - Shares closed at $36.90, up 7.96%, on October...
JPMorgan Bets Big on Definium's Brain Drug — But Can a Small Biotech Really Double From Here?
Shares of Definium Therapeutics surged 10.2% to $37.65 on October 9 after JPMorgan initiated coverage with an Overweight rating and an $84 price target —...
🟢 Definium Therapeutics is trading 10% up today after JPMorgan initiated coverage with an Overweight rating
Definium Therapeutics is trading at $37.65 (+10.15%) after JPMorgan initiated coverage with an Overweight rating. - JPMorgan set an $84 price target and...
🟢 Definium Therapeutics rises 4.2% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🟢 Definium Therapeutics is trading 4.04% up in pre-market amid broad-market strength that may support the move
Definium Therapeutics is trading at $35.56 (+4.04%) in pre-market, with broad-market strength potentially supporting the move, though no direct link is...
🔴 Definium Therapeutics is trading 4.45% down amid biotech-sector weakness
Definium Therapeutics is trading 4.45% lower at $33.53 on October 8, 2026, amid biotech-sector weakness and broader risk-off pressure. - XBI is down 2.04%;...
🔴 Definium Therapeutics is trading 5% down today amid possible biotech-sector weakness
Definium Therapeutics is trading 5% lower at $34.43, with possible biotech-sector weakness the leading explanation for the October 6 move. - No clear...
🟢 Definium Therapeutics is trading 7.34% up in pre-market with no identified catalyst
Definium Therapeutics is trading at $41.01, up 7.34% in pre-market; no confirmed company-specific catalyst was found for September 30. - Positive Phase 3...
🟢 Definium Therapeutics is trading 4.6% up today
Definium Therapeutics is trading at $37.84, up 4.60% during the September 28, 2026 session, with no fresh company-specific announcement identified to explain...
🔴 Definium Therapeutics is trading 4.12% down today as 10-year Treasury yield hits a 19-year high
Definium Therapeutics is trading 4.12% down at $36.10 as rising Treasury yields pressure growth-oriented biotech stocks. - The 10-year Treasury yield surged to...
🔴 Definium Therapeutics is trading 4.2% down today as crude and Treasury yields pressure valuations
Definium Therapeutics is trading 4.2% down at $38.64 as broader risk-off sentiment weighs on equities. - The Nasdaq Composite is down 1.10%, while rising crude...
🟢 Definium Therapeutics rises 4.5% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Definium Therapeutics is trading 4.22% up today after positive Phase 3 Panorama results
Definium Therapeutics is trading 4.22% up at $38.38 after investors continued responding to positive Phase 3 Panorama results for DT120 in generalized anxiety...
🔴 Definium Therapeutics falls 5.0% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
DFTX Announces Positive Phase 3 Results for DT120 in Generalized Anxiety Disorder
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder (GAD)....
🟢 Definium Therapeutics is trading 8.90% up today after DT120 reduced anxiety symptoms in second trial
Definium Therapeutics is trading at $42.50 (+8.90%) after DT120 reduced generalized-anxiety symptoms in a second successful late-stage trial. - The...
Definium's Anxiety Drug Aces a Second Late-Stage Trial — But Can a Psychedelic Pill Justify a $6 Billion Valuation?
Shares of Definium Therapeutics surged 19.3% in pre-market trading to $46.41 after the company reported that its experimental anxiety pill cleared the final...
🟢 Definium Therapeutics Surges 19.35% in Pre-Market Following Positive Phase 3 Panorama Study Results
- Definium Therapeutics is trading 19.35% up in pre-market at $46.41 following the announcement of positive topline results from its Phase 3 Panorama study of...